Gallus BioPharmaceuticals

Gallus BioPharmaceuticals was a leading contract manufacturer specializing in mammalian cell culture for biologic drugs. The company provided clinical and commercial manufacturing services for monoclonal antibodies and complex proteins at FDA-approved facilities in St. Louis, MO and Princeton, NJ. It had an exemplary regulatory record and supported products such as Stelara and Remicade for Janssen Pharmaceuticals as well as ProstaScint.

The company was acquired by Patheon in September 2014.

No proprietary clinical pipeline; focused on client manufacturing.

At its peak before acquisition, it employed approximately 370 people.

Investors included Ridgemont Equity Partners.

Notable expansion of process development labs with single-use technologies prior to acquisition.

Facilities were cGMP-compliant with both stainless steel and flexible single-use systems.

After the acquisition by Patheon, operations continued under the Patheon brand.